BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines.The company has acquired MediLink Therapeutics' ADC technology and is...
Source LinkBioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines.The company has acquired MediLink Therapeutics' ADC technology and is...
Source Link
Comments